Novavax Inc. shares shares sank in the extended session Tuesday after the biotech drug maker posted more than double the loss that analysts expected and reorganized with concerns it may not be in business in a year.
“While our current cash flow forecast for the one-year going concern look-forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration,”…
Source: finance.yahoo.com
Related posts:
S&P 500 Sees Worst Fed Day Since 2001; Yields Up: Markets Wrap
This Is This Best Age to Retire
‘Bear down’ and ‘be as frugal as you can’: Baby-boomer financial experts speak from experience on wa...
3 Heavily Shorted Stocks That Are Down More Than 75% Since 2021. Can They Turn Things Around?
A long-time market bear who called the 2000 and 2008 crashes warns the S&P 500 could plummet 64%...